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Abstract
Background: The World Health Organization (WHO) recommends that the cost effectiveness of introducing
human papillomavirus (HPV) vaccination is considered before such a strategy is implemented. However, developing
countries often lack the technical capacity to perform and interpret results of economic appraisals of vaccines. To
provide information about the feasibility of using such models in a developing country setting, we evaluated
models of HPV vaccination in terms of their capacity, requirements, limitations and comparability.
Methods: A literature review identified six HPV vaccination models suitable for low-income and middle-income
country use and representative of the literature in terms of provenance and model structure. Each model was
adapted by its developers using standardised data sets representative of two hypothetical developing countries (a
low-income country with no screening and a middle-income country with limited screening). Model predictions
before and after vaccination of adolescent girls were compared in terms of HPV prevalence and cervical cancer
incidence, as was the incremental cost-effectiveness ratio of vaccination under different scenarios.
Results: None of the models perfectly reproduced the standardised data set provided to the model developers.
However, they agreed that large decreases in type 16/18 HPV prevalence and cervical cancer incidence are likely to
occur following vaccination. Apart from the Thai model (in which vaccine and non-vaccine HPV types were
combined), vaccine-type HPV prevalence dropped by 75% to 100%, and vaccine-type cervical cancer incidence
dropped by 80% to 100% across the models (averaging over age groups). The most influential factors affecting
cost effectiveness were the discount rate, duration of vaccine protection, vaccine price and HPV prevalence.
Demographic change, access to treatment and data resolution were found to be key issues to consider for models
in developing countries.
Conclusions: The results indicated the usefulness of considering results from several models and sets of modelling
assumptions in decision making. Modelling groups were prepared to share their models and expertise to work
with stakeholders in developing countries.
Please see related article: http://www.biomedcentral.com/1741-7007/9/55
Background
Cervical cancer is the second most common cause of
cancer-related death in women worldwide, with about
500,000 newly diagnosed cases and 250,000 related
deaths occurring every year, mostly in low-income and
middle-income countries [1]. Two prophylactic vaccines
against human papillomavirus (HPV), the necessary
cause of cervical cancer, have been shown to be effica-
cious against HPV infection and precursors of cervical
cancer [2,3]. Both of these protect against HPV types 16
and 18, which are responsible for about 70% of invasive
cervical cancer cases [4]. The two vaccines differ in
aspects not related to their protection against cervical
cancer due to vaccine-type HPV, such as their valency,
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licensure as well as the degree of protection against
non-vaccine type HPV infection reported in clinical
trials [5].
Policymakers are faced with decisions about the intro-
duction of one of the two HPV vaccines in routine
immunisation programmes. The World Health Organi-
zation (WHO) recommends that the cost effectiveness
of introducing a new vaccine to the national immunisa-
tion programme is considered before such a strategy is
implemented [6], and has reiterated this advice for the
case of HPV vaccination [7]. In recent years, health eco-
nomic evaluation and modelling have played an impor-
tant role in decisions about HPV vaccination in high-
income countries [8,9]. However, there is less evidence
that economic evaluations have had such a role in low-
income and middle-income countries, despite the avail-
ability of results from several studies based in these
countries [10-14]. A major difficulty is that these coun-
tries often lack the technical capacity to perform and
interpret results of economic appraisals of vaccines,
which, in the absence of country contextualisation, is
believed to have sometimes led to suboptimal decision
making about vaccine introduction [15].
Existing literature reviews of models of HPV-related pre-
ventative strategies have mainly [16-20] or solely [21-24]
focused on high-income countries. In addition, the reviews
mainly discuss the results of previous adaptations of cost-
effectiveness models rather than their potential for appli-
cation to new settings. Review authors have usually not
had access to most of the models that they were reviewing,
and hence have not been able to compare model results
when applied to a common data set and assumptions.
Hence they may provide useful summaries to policy-
makers in (mainly high-income) countries where multiple
analyses have already been conducted, but are less useful
in exploring the feasibility of applying models to low-
income or middle-income settings.
Decision makers in low-income and middle-income
countries have requested WHO guidance on the
strengths and potential limitations of existing mathema-
tical models produced by both public and private sector
analysts to inform HPV vaccine introduction decisions.
The purpose of this paper is to assess existing economic
models of HPV vaccination in terms of their capability,
requirements, robustness and limitations, particularly
when applied to a low-income or middle-income coun-
try setting. This information is meant to provide policy-
makers in these countries with information about the
feasibility of applying these models to inform their own
decision making, as well as guidance in interpreting
their results. The objective is to provide a menu of
potentially useful models and their key characteristics,
rather than to recommend a particular model.
Methods
Literature review and model selection
In order to survey existing economic models of HPV
vaccination, the Ebscohost, Embase, PubMed and Scien-
ceDirect databases were searched for economic evalua-
tions of HPV vaccination. Articles were included if they
were full research papers describing an economic eva-
luation (cost effectiveness, cost utility or cost-benefit
analysis) of vaccination against HPV to reduce the inci-
dence of cervical cancer and/or its precursor lesions,
were published before February 2010 and were written
in English, Dutch, G e r m a n ,S p a n i s h ,I t a l i a no rF r e n c h .
Additional file 1 gives the search terms used and num-
ber of studies found.
A subset of the models identified in the literature
review, together with an additional model discussed in
the grey literature [25] and later published [26], were
selected for a more detailed comparison. Models were
chosen based on the willingness of model developers to
participate in the study as well as to ensure representa-
tion of models with the following characteristics: model
development by authors from institutions in low-income
or middle-income countries, previous model application
to low-income or middle-income settings, both public
sector and pharmaceutical industry provenance, as well
as being representative of different model structures
(static/dynamic, aggregate/individual based) represented
in the literature. Industry models were included in order
to provide guidance to decision makers in low-income
and middle-income countries who are often confronted
with results from such models, and sometimes have no
other source of cost-effectiveness information.
Evaluation of hypothetical scenarios
In order to compare the robustness and applicability of
the models, model developers were provided with stan-
dardised scenarios consisting of input data sets for two
hypothetical countries: a low-income country and a
middle-income country. For the hypothetical low-
income country, parameters for demographics, HPV epi-
demiology and treatment costs were assembled from
low-income countries in the WHO Africa region. For
the hypothetical middle-income country, the parameters
were assembled from lower-middle-income countries in
the WHO South-East Asia and Western Pacific regions
(details are given in Additional file 2). Model developers
were asked to use their models to evaluate the cost
effectiveness of adding adolescent HPV 16/18 vaccina-
tion either to a situation with no organised cervical
screening (for the hypothetical low-income country), or
to a situation with some limited screening (in the
hypothetical middle-income country). Screening was
assumed to be performed by either visual inspection
with acetic acid (VIA) or Pap smear (see Additional file
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Page 2 of 92). The analysis of the impact of vaccination was limited
to cervical cancer outcomes only.
T h es t a n d a r d i s e dd a t as e t st h a tw e r ep r o v i d e dt o
model developers included demographic, epidemiologi-
cal and economic parameters (see Additional file 2).
Natural history parameters (such as transition rates
between different precancer neoplasia stages) are
expected to be largely independent of country, ignoring
the possible effects of factors such as HIV coinfection
and nutrition. Hence model developers were asked to
use the original parameter set that they used for what
they considered to be a general ‘base case’ model, either
in a representative low-income or middle-income set-
ting, or in what they considered to be their main model-
ling publication. They were also asked to use their
original model assumptions for cancer diagnosis, treat-
ment, staging, recovery and recurrence.
Developers were asked to provide results of the eva-
luation within a month of receiving the standardised
data set. They were requested to provide both epidemio-
logical (for example, HPV prevalence, cervical cancer
incidence) and economic (for example, discounted and
undiscounted costs and disease-weighted life years
saved) results. One-way sensitivity analyses on discount
rates, duration of vaccine protection, key costs and utili-
ties as well as the prevalence of HPV infection were also
requested. Lastly, model developers were asked to fill in
a questionnaire on how long the exercise took, the level
of expertise needed to conduct it, and the extent to
which they were willing to share model software, code
and documentation with potential partners in low-
income and middle-income countries. Developers then
met with HPV vaccinologists, epidemiologists and policy
advisors in order to discuss the findings.
Results
Literature review and model selection
The literature review identified 58 articles on economic
evaluations of HPV vaccination. Based on the World
Bank classification of countries by income level, 41 sin-
gle-country studies were set in high-income countries;
these describe the cost effectiveness of vaccination in 18
different high-income countries. In addition, six single-
country studies were set in three upper-middle-income
countries (Brazil, Mexico and South Africa), while two
single-country studies were set in lower-middle-income
countries (India and Vietnam). There were no identified
single-country studies set in low-income countries.
There were also nine multicountry studies; three of
these were set in high-income countries, four in low-
income or middle-income countries and two in both
high-income and low-income/middle-income countries.
Hence high-income countries were far more strongly
represented in the overall literature. Indeed, some
countries (USA, UK and The Netherlands) had the ben-
efit of three or more economic evaluations conducted
by separate groups. In contrast, in low-income and mid-
dle-incomecountries (apart from Brazil and Mexico),
evidence is scarce, and at best relies on either a single
study or part of a multicountry or regional analysis. For
instance, the cost effectiveness of HPV vaccination in all
72 Global Alliance for Vaccines and Immunisation
(GAVI)-eligible countries is described in a single publi-
cation [14]. Details of the identified articles are given in
Additional file 3.
Despite the large number of publications, the majority
of studies were conducted based on a model that had
been previously described; either the same model in a
different context, or an adapted version of a previously
used model. It was explicitly mentioned in 35 of these
articles that the model used in the study had been used
previously.
Six models were selected for inclusion in the compari-
son exercise: (i) the Harvard model [10], (ii) the WHO-
CHOICE (’CHOosing Interventions that are Cost Effec-
tive’) model [13], (iii) the Thai model [26], (iv) the South
African model [12], (v) the Merck model [27] and (vi) the
GlaxoSmithKline (GSK) model [28]. The selection
includes two with wide applicability to many countries
including low-income and/or middle-income countries
(Harvard and WHO-CHOICE models), two developed by
modellers based in middle-income countries with specific
application to their own countries (Thai and South Afri-
can models), and one from each of the manufacturers of
the two licensed HPV vaccines (Merck and GSK models).
All six models have been applied to low-income and/or
middle-income countries. They also encompass the range
of structures used in models of HPV vaccination includ-
ing Markov (GSK, South Africa, WHO-CHOICE), semi-
Markov (Thai), compartmental dynamic (Merck) and sta-
tic individual based (Harvard). In the cases where groups
had multiple modelling tools, only one was selected for
the exercise. Key characteristics of the models are shown
in Additional file 4.
Evaluation of hypothetical scenarios
Figure 1 shows the different model estimates of age-spe-
cific HPV 16/18 prevalence and cervical cancer inci-
dence for the two hypothetical countries before and
after vaccination. None of the models perfectly repro-
duced either HPV prevalence or cervical cancer inci-
dence in the standardised data set provided to the
model developers. In particular, they had difficulty
reproducing very low HPV 16/18 prevalence levels in
the hypothetical middle-income country. However, most
models agreed that large (up to 100%) decreases in type
16/18 HPV prevalence and cervical cancer incidence are
likely to occur following vaccination.
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Page 3 of 9The relationship between HPV prevalence and cervical
cancer incidence in a model depends on its representa-
tion of the natural history of cervical disease. Developers
used different approaches to adapt their models to dif-
ferent outcomes. The South African model used HPV
prevalence data as a direct input. The GSK and Merck
models adjusted the force of HPV infection in order to
fit to cervical cancer data. Since natural history
parameters were kept constant, this sometimes led to a
worse fit to HPV prevalence data. The Thai model
grouped all (vaccine and non-vaccine type) HPV-related
outcomes, and assumed that 70% of cervical cancer
cases were the result of HPV 16/18 infection to fit to
data. For the Harvard model, developers selected the
profile from an existing suite of prefitted models that
best fit the data. This resulted in a fit that was less good
Figure 1 Human papillomavirus (HPV) prevalence and cervical cancer incidence from each model. Pre/post-vaccination HPV prevalence
and cervical cancer incidence for type 16 and 18 HPV from each of the six models compared to figures in the standardised data set, for the
hypothetical low-income country (top graph) and middle-income country (bottom graph). The Thai model shows HPV prevalence for all high-risk
HPV types but cancer incidence for only type 16 and 18 related HPV infection.
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WHO-CHOICE model used cervical cancer incidence
data as a direct input into the model, but adjusted this
using a regional specific estimate of the proportion of
cancer cases caused by HPV 16/18, then applied pre-
existing vaccine efficacy estimates.
Figure 2 shows model estimates of the incremental
costs, utilities and cost-effectiveness ratios of vaccination
for both settings. Most models predicted the ratio to be
around US$1,000 to US$2,000 per disease-weighted life
year gained for both countries. However, the South Afri-
can model indicated lower incremental cost-effectiveness
ratios than the others, while the Thai model indicated
higher incremental cost-effectiveness ratios for the
hypothetical low-income country. The most influential
factors affecting cost effectiveness across all models
were the rate of discounting, duration of vaccine protec-
tion, vaccine price and HPV prevalence. These para-
meters have also been found to be influential in reviews
of HPV models in high-income countries [21,22].
Figure 2 Incremental cost-effectiveness ratios for vaccination from each model. Discounted incremental cost-effectiveness ratios for
vaccination in the hypothetical low-income (top graph) and middle-income (bottom graph) countries, using each of the six models. Dotted
lines show gross domestic product (GDP) per capita for the hypothetical country. Missing bars indicate that results were not available for that
model.
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The model comparison exercise and subsequent discus-
sions highlighted a number of key issues that affect
model-based analyses based in low-income or middle-
income settings.
Demographic change
The absolute incidence of cervical cancer predicted by
many of the models for the hypothetical low-income
country exceeds that of most of the low-income coun-
tries in the world, even though the age-dependent inci-
dence of cervical cancer in the hypothetical data set is
typical of many of these countries. The main reason is
because the population structure of low-income coun-
tries is not currently in equilibrium since the number of
births far exceeds the number of deaths each year. For
instance, prevaccination cancer incidence predicted by
many of the models for the hypothetical low-income
country is higher than that of most low-income African
countries. An open population model may be able to
capture the current population structure and its likely
changes in the future. However, a closed population
model (such as a cohort model) may predict a higher
absolute incidence of cancer compared to an open
model since the cohort will be larger than older cohorts
currently observed. Both kinds of models may predict a
higher absolute incidence of cancer than current statis-
tics indicate, and hence overestimate the cost effective-
ness of vaccination.
Data resolution
HPV-related outcome data for many low-income and
middle-income countries are poor, and often highly
aggregated. For example, cervical cancer incidence avail-
able from the WHO/Institut Català d’Oncologia Infor-
mation Centre on HPV and Cervical Cancer [29] is
stratified into the age groups 0-14, 15-44, 45-54, 55-64
and ≥65 years. Models with very simple natural history
representations may thus predict that 15-year-old
women have the same cancer incidence as 44-year-old
women, hence overestimating the projected incidence of
c a n c e ri ny o u n g e rw o m e nd u et ot h el a r g es i z eo ft h e
15-44-year-old age band. Overestimating the proportion
of cancers occurring in younger women may cause the
cost effectiveness of vaccination prior to sexual debut to
be overestimated (since more life years are lost by can-
cer occurring at a young age). However, it may cause
the cost effectiveness of vaccination of older women to
be underestimated (because vaccination is assumed to
occur too late to protect many of these women). More
sophisticated models may be able to capture the time
lag between the peak incidence of HPV infection and of
cervical cancer by using progression rates based on
model fits to countries with more data, and hence
correctly predict that cervical cancer incidence is higher
in adults than in adolescents.
Access to treatment
HPV vaccination models in high-income countries gen-
erally assume that all women with diagnosed cancer
receive treatment. This assumption may not be accurate
in many low-income and middle-income countries.
Lower access to treatment will increase both the net
cost of vaccination (because fewer health care savings
are made by reducing HPV-related outcomes), and the
net benefit of vaccination (because more utilities are lost
for each cancer case). This could affect the incremental
cost-effectiveness ratio in either direction. For instance,
the WHO-CHOICE model estimated that reducing
treatment coverage in the hypothetical low-income
country from 100% to 20% would decrease the incre-
mental cost-effectiveness ratio of HPV vaccination from
US$647 to US$507 per disease-weighted life year gained.
Accessibility of models
Table 1 summarises the accessibility of the models used
in the exercise in terms of their complexity and avail-
ability to new users. Models containing a user interface
were generally more available to new users; developers
of more complex models were more reluctant to pub-
licly release their models without the opportunity to
train new users.
Discussion
Six models were used to evaluate the cost effectiveness
of HPV vaccination of adolescent girls in two hypotheti-
cal scenarios typical of a low-income and middle-income
country. Despite differences in model type, structure,
assumptions and complexity, the models reached con-
clusions that were qualitatively similar about the cost
effectiveness of vaccination, although they displayed
diverse quantitative features particularly in sensitivity
analyses.
The data sets given to model developers were
hypothetical and not meant to inform decision making
for any actual country. Furthermore, a number of sim-
plifications were made to the exercise. For example, the
exercise focused on the most important proven benefit
of HPV vaccination, that is, the prevention of cervical
cancer and its precursor lesions due to HPV type 16
and 18 infection. Protection against other endpoints
(including genital warts, non-cervical HPV-linked can-
cers and crossprotection against non-vaccine type infec-
tion) were not considered. In a real-world setting, these
endpoints may provide substantial additional benefits to
vaccination. Also, model developers were given a month
to conduct the exercise, following receipt of the standar-
dised data set. They were asked to restrict themselves to
Jit et al. BMC Medicine 2011, 9:54
http://www.biomedcentral.com/1741-7015/9/54
Page 6 of 9a single model, even though some groups had several
models that they could deploy, often in order to cross-
validate results. This simulates a typical real-world situa-
tion in low-income and middle-income countries, where
there may be constraints on the time and resources
available to conduct an economic evaluation. The lim-
ited time to conduct the exercise required other trade
offs of the investigators. For example, they were asked
not to alter their existing natural history parameters to
better fit outcome data provided, which may account for
the variation in model predictions of HPV prevalence
and cervical cancer incidence, as well as the difficulty
some models had in accurately reproducing both out-
comes in the same model. Also, only one-way sensitivity
analysis was performed. In practice, investigators may
typically conduct multidirectional, probabilistic and sce-
nario sensitivity analyses to capture uncertainty in HPV
natural history and epidemiology.
Only a subset of available HPV models was evaluated.
The models selected were some of those perceived to be
potentially useful for deployment in low-income and mid-
dle-income settings; however, this does not imply that
other available models (either from the same or from
other model developers) could not also be used. Also, the
type of model to be used will depend on the kind of ques-
tion that needs to be answered. For example, a dynamic
model would be needed to investigate the impact of herd
immunity, and the incremental benefit of interventions
that rely on this effect, such as catch-up campaigns. How-
ever, the input and computational power needed for such
a model may not be available in all settings.
While unrealistic for directly informing policy, the results
of this exercise are useful for identifying features of models
and model comparisons that are useful to policymakers
wishing to commission cost-effectiveness evaluations. The
results of the exercise suggest that even when using a stan-
dardised data set, there are important differences between
model predictions, although broad qualitative features are
common to most model results. This finding highlights the
importance of not relying on a single model type or set of
modelling assumptions for decision making. If independent
models using different structures and assumptions reach
similar qualitative results (such as HPV vaccination being
cost effective under a particular threshold) there may be
greater confidence in the robustness of such conclusions.
This is particularly the case for low-income and middle-
income countries that are limited by lack of input data, and
hence may have to make assumptions where data are not
available.
Specific recommendations for model developers and
policy makers are listed in the Appendix.
Conclusions
Evidence about the cost effectiveness of HPV vaccina-
tion in low-income and middle-income countries is
scarce. Policymakers in these countries often do not
have the benefit of using results from an array of cost-
effectiveness studies conducted in their country, unlike
their counterparts in countries such as the USA, UK
and The Netherlands. Furthermore, they often lack the
technical capacity to use such models and interpret
their results. However, the response to this exercise
demonstrates that modelling groups are prepared to
share their models and expertise to work with stake-
holders in low-income and middle-income countries.
This exercise and its findings should improve knowledge
about the range of models available as well as many of
the features to consider when using them.
Appendix
Recommendations
For model developers
(1) Model developers evaluating vaccination in low-
income and/or middle-income countries should ideally
Table 1 Accessibility of the models
GSK Harvard Merck South African Thai WHO-CHOICE
Complexity of evaluation for this exercise:
System used Desktop PC Linux cluster Desktop PC Desktop PC Desktop PC Desktop PC
Coding platform Excel C++ Mathematica TreeAge Excel VBA Excel VBA
Time taken (person h) 30 15 20 12 25 32
Availability to new users:
Source code X X
Front end X X (web based) X X
Documentation X X X
Availability 1 3 2 3 2 1
Accessibility of the models in terms of their complexity (based on the evaluation conducted for this exercise) and availability to new users. Availability of the
model to new users is rated according to the following: (1) freely available for anyone to use, (2) may be available as part of collaboration under supervision by
developers, (3) may be available to apply to new settings provided the evaluation is conducted by developers.
WHO-CHOICE = World Health Organization ‘CHOosing Interventions that are Cost Effective’ model; VBA = visual basic application.
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effects of demographic change, low data resolution and
poor access to cancer treatment where relevant.
(2) Models with a range of types, structures, assump-
tions and complexity may give broadly similar results
about the cost effectiveness of routinely vaccinating girls
in early adolescence, although they may not all be able
to perfectly fit prevaccination outcome data.
For decision makers
(1) The models evaluated here appear to be suitable for
evaluating the cost effectiveness of routinely vaccinating
girls in early adolescence.
(2) Decision making should ideally be informed by
several different models; agreement among models gives
greater confidence in the robustness of conclusions.
(3) Model developers are prepared to share their mod-
els and expertise, and hence could be approached by
decision makers in low-income and middle-income
countries wishing to evaluate vaccination options.
Additional material
Additional file 1: Literature review search strategy. Search strategy
used for the literature review of economic evaluations of human
papillomavirus (HPV) vaccination.
Additional file 2: Standardised data set and data sources used to
inform it. Details on the standardised data sets for the hypothetical low-
income and middle-income countries, as well as the data sources used
to inform it.
Additional file 3: Articles on economic evaluations of human
papillomavirus (HPV) vaccination. Articles identified as economic
evaluations of HPV vaccination during the literature search published
before February 2010.
Additional file 4: Key characteristics of the models involved in the
exercise. Details on the provenance, type, structure, parameters,
capabilities and outcomes presented of the models involved in the
exercise.
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